Cargando…
Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
INTRODUCTION: It is elusive to compare the efficacy and safety of abrocitinib 100 mg versus 200 mg once daily in patients with atopic dermatitis. AIM: This meta-analysis aims to explore the influence of abrocitinib 100 mg versus 200 mg on the treatment of atopic dermatitis. MATERIAL AND METHODS: Sev...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704456/ https://www.ncbi.nlm.nih.gov/pubmed/36457683 http://dx.doi.org/10.5114/ada.2022.114925 |
_version_ | 1784840057873498112 |
---|---|
author | Wang, Junqiao Yang, Yuanjuan Yang, Haitao Fu, Xiaojuan |
author_facet | Wang, Junqiao Yang, Yuanjuan Yang, Haitao Fu, Xiaojuan |
author_sort | Wang, Junqiao |
collection | PubMed |
description | INTRODUCTION: It is elusive to compare the efficacy and safety of abrocitinib 100 mg versus 200 mg once daily in patients with atopic dermatitis. AIM: This meta-analysis aims to explore the influence of abrocitinib 100 mg versus 200 mg on the treatment of atopic dermatitis. MATERIAL AND METHODS: Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library were systematically searched through July 2021. We included randomized controlled trials (RCTs) assessing the effect of abrocitinib 100 mg versus 200 mg for patients with atopic dermatitis. RESULTS: Four RCTs were included in the meta-analysis. Compared with abrocitinib 100 mg for atopic dermatitis, abrocitinib 200 mg had a remarkably positive impact on IGA response (OR = 1.78; 95% CI: 1.39–2.28; p < 0.00001), EASI-75 (OR = 2.03; 95% CI: 1.60–2.57; p < 0.00001), NRS response (OR = 1.97; 95% CI: 1.27–3.08; p = 0.003), and adverse events (OR = 1.43; 95% CI: 1.11–1.84; p = 0.005), but it showed no obvious influence on serious adverse events (OR = 0.59; 95% CI: 0.25–1.37; p = 0.22). CONCLUSIONS: Abrocitinib 200 mg is better than abrocitinib 100 mg for the treatment of atopic dermatitis. |
format | Online Article Text |
id | pubmed-9704456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-97044562022-11-30 Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials Wang, Junqiao Yang, Yuanjuan Yang, Haitao Fu, Xiaojuan Postepy Dermatol Alergol Original Paper INTRODUCTION: It is elusive to compare the efficacy and safety of abrocitinib 100 mg versus 200 mg once daily in patients with atopic dermatitis. AIM: This meta-analysis aims to explore the influence of abrocitinib 100 mg versus 200 mg on the treatment of atopic dermatitis. MATERIAL AND METHODS: Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library were systematically searched through July 2021. We included randomized controlled trials (RCTs) assessing the effect of abrocitinib 100 mg versus 200 mg for patients with atopic dermatitis. RESULTS: Four RCTs were included in the meta-analysis. Compared with abrocitinib 100 mg for atopic dermatitis, abrocitinib 200 mg had a remarkably positive impact on IGA response (OR = 1.78; 95% CI: 1.39–2.28; p < 0.00001), EASI-75 (OR = 2.03; 95% CI: 1.60–2.57; p < 0.00001), NRS response (OR = 1.97; 95% CI: 1.27–3.08; p = 0.003), and adverse events (OR = 1.43; 95% CI: 1.11–1.84; p = 0.005), but it showed no obvious influence on serious adverse events (OR = 0.59; 95% CI: 0.25–1.37; p = 0.22). CONCLUSIONS: Abrocitinib 200 mg is better than abrocitinib 100 mg for the treatment of atopic dermatitis. Termedia Publishing House 2022-03-27 2022-10 /pmc/articles/PMC9704456/ /pubmed/36457683 http://dx.doi.org/10.5114/ada.2022.114925 Text en Copyright: © 2022 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Wang, Junqiao Yang, Yuanjuan Yang, Haitao Fu, Xiaojuan Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials |
title | Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials |
title_full | Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials |
title_fullStr | Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials |
title_full_unstemmed | Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials |
title_short | Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials |
title_sort | abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704456/ https://www.ncbi.nlm.nih.gov/pubmed/36457683 http://dx.doi.org/10.5114/ada.2022.114925 |
work_keys_str_mv | AT wangjunqiao abrocitinib100mgversus200mgforatopicdermatitisametaanalysisofrandomizedcontrolledtrials AT yangyuanjuan abrocitinib100mgversus200mgforatopicdermatitisametaanalysisofrandomizedcontrolledtrials AT yanghaitao abrocitinib100mgversus200mgforatopicdermatitisametaanalysisofrandomizedcontrolledtrials AT fuxiaojuan abrocitinib100mgversus200mgforatopicdermatitisametaanalysisofrandomizedcontrolledtrials |